AveXis Inc. (AVXS)

217.83
0.18 0.08
Prev Close 217.65
Open 217.78
Day Low/High 217.71 / 217.94
52 Wk Low/High 65.54 / 217.94
Volume 884.12K
Avg Volume 858.10K
Exchange
Shares Outstanding 36.82M
Market Cap 8.02B
EPS -7.30
Div & Yield N.A. (N.A)
AveXis To Report Third Quarter 2017 Financial And Operating Results

AveXis To Report Third Quarter 2017 Financial And Operating Results

Conference call and webcast on November 9 at 4:30 p.m. EST

AveXis Announces New England Journal Of Medicine Publication Of Phase 1 Data Of AVXS-101 Gene Replacement Therapy In Spinal Muscular Atrophy Type 1

AveXis Announces New England Journal Of Medicine Publication Of Phase 1 Data Of AVXS-101 Gene Replacement Therapy In Spinal Muscular Atrophy Type 1

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, announced data as of August 7, 2017, from the...

Short Interest Decreases By 16.8% For AVXS

Short Interest Decreases By 16.8% For AVXS

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 735,315 share decrease in total short interest for AveXis Inc , to 3,638,567, a decrease of 16.81% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

AveXis To Report Second Quarter 2017 Financial And Operating Results

AveXis To Report Second Quarter 2017 Financial And Operating Results

-- Conference call and webcast on August 10 at 4:30 p.m. EDT --

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Six charts showing signs of smart money footprints.

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.

AveXis And REGENXBIO Announce New Exclusive Worldwide Licenses For The Treatment Of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector

REGENXBIO grants AveXis new licenses to NAV AAV9 vector for the development and commercialization of treatments for Rett syndrome (RTT) and amyotrophic lateral sclerosis (ALS)

First Week of AVXS July 21st Options Trading

Investors in AveXis Inc saw new options begin trading this week, for the July 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXS options chain for the new July 21st contracts and identified one put and one call contract of particular interest.

AveXis Reports First Quarter 2017 Financial And Operating Results

- Conference call of April 25 was in lieu of Q1 2017 earnings call -

AveXis To Report First Quarter 2017 Financial And Operating Results

Results to be reported on May 11, 2017

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids

Investors focus on a drug's efficacy and safety. Much less time is spent considering the importance of manufacturing, even though it is a vital step in the drug approval process.

AveXis, Esperion and Amgen Among Biotech Movers

AveXis, Esperion and Amgen Among Biotech Movers

AveXis, Esperion Therapeutics, Medicines Co. and Amgen were among the biotech stock movers Friday morning.

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

AveXis Reaches Analyst Target Price

In recent trading, shares of AveXis Inc have crossed above the average analyst 12-month target price of $68.50, changing hands for $68.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AveXis To Present Results From Phase 1 Trial Of AVXS-101 In SMA Type 1 At AAN Annual Meeting

-- Key preclinical and clinical data of AVXS-101 in SMA to be presented --

3 Stocks Setting Up for Major Breakouts

3 Stocks Setting Up for Major Breakouts

Here's how to rake in the gains off some potential major breakouts.

AveXis Announces Single-Arm Design For European Pivotal Study Of AVXS-101 In SMA Type 1 Patients

Company provides update following receipt of Scientific Advice response from the EMA

AveXis Gene Therapy AVXS-101 Granted Access Into EMA PRIME Program For Spinal Muscular Atrophy Type 1

PRIME intended to optimize development and speed evaluation of AVXS-101 through enhanced interactions and early dialogue with EMA